Pancreatic Cancer Research

ResearcherVA Greater Los Angeles Healthcare SystemActive in the last 2 years

Neil A. Bhowmick

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8747-5989; OpenAlex author ID A5057426165; NIH RePORTER profile ID 2565214. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
1
Labs led
1
Collaborators
22
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper, 1 grant · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. L-Glutamine in combination with first-line gemcitabine and nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: an open-label, single-arm, phase 1 Glut… Last author DOI 10.1038/s43018-026-01225-z↗
  2. HDAC4/MybL1/YAP novel signaling axis is required for pancreatic cancer metastasis to the liver. Co-author DOI 10.7150/ijbs.102132↗
  3. Fecal Microbiome Composition and Plasma Metabolomics in Pancreatic Cancer Cachexia Treated with Nutritional Support Co-author DOI 10.20944/preprints202401.0727.v1↗
  4. Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivity Last author DOI 10.21203/rs.3.rs-3647514/v1↗
  5. Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol. Co-author DOI 10.3390/biomedicines11051392↗
  6. Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15113020↗
  7. Gut microbiome and pancreatic cancer cachexia: An evolving relationship. Co-author DOI 10.4251/wjgo.v14.i7.1218↗
  8. An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice. Co-author DOI 10.1053/j.gastro.2018.08.028↗

Grants 1

  1. Project 2 - Fatty Liver Predisposes to Metastasis: Role of Hepatic Stellate Cells P01CA233452↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Arsen Osipov · 6 shared papers, 2022–2026 · strength 1.11
  2. Andrew Eugene Hendifar · 6 shared papers, 2022–2026 · strength 1.05
  3. Hayato Muranaka · 6 shared papers, 2022–2026 · strength 1.05
  4. Jun Gong · 6 shared papers, 2022–2026 · strength 1.05
  5. Stephen Jacob Pandol · 5 shared papers, 2018–2026 · strength 0.82
  6. Shelly Chi-Loo Lu · 1 shared grant, 2024 · strength 0.72
  7. Ekihiro Seki · 1 shared grant, 2024 · strength 0.72
  8. Mouad Edderkaoui · 4 shared papers, 2018–2026 · strength 0.65
  9. Omer Hany Miligy Elmadbouh · 3 shared papers, 2023–2026 · strength 0.59
  10. Natalie Moshayedi · 3 shared papers, 2022–2024 · strength 0.51
  11. Veronica Placencio-Hickok · 2 shared papers, 2023–2024 · strength 0.37
  12. Ramachandran Murali · 2 shared papers, 2018–2025 · strength 0.28
  13. Yan Ou · 1 shared paper, 2025 · strength 0.21
  14. Dina Hauptschein · 1 shared paper, 2025 · strength 0.21
  15. Raul A. Urrutia · 1 shared paper, 2025 · strength 0.21
  16. Nicholas P. Tatonetti · 1 shared paper, 2023 · strength 0.17
  17. Abrahm Levi · 1 shared paper, 2023 · strength 0.16
  18. Qiang Wang · 1 shared paper, 2018 · strength 0.07
  19. Aida Habtezion · 1 shared paper, 2018 · strength 0.07
  20. László G. Boros · 1 shared paper, 2018 · strength 0.07
  21. Jian Tajbakhsh · 1 shared paper, 2018 · strength 0.07
  22. Richard Tuli · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.